-
Mashup Score: 4NORD Breakthrough Summit | Rare Disease Conference - 10 month(s) ago
NORD Summit is one of the largest events in rare disease, bringing together participants spanning the rare community.
Source: NORD Rare SummitCategories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 0Abstract Submission - NORD Rare Summit - 10 month(s) ago
Main Point of ContactAll correspondence with NORD, including decision notification, will be through the main point of contact.Company/Organization Affiliation*Main Point of Contact’s Email*Main Point of Contact’s Phone Number*Abstract Author DetailsList all authors (up to 14) in the order they should appear. Please list each author’s last name followed by their first and middle initials,…
Source: NORD Rare SummitCategories: Latest Headlines, Rare DiseaseTweet-
Only 1 week left to submit your poster abstract for this year's #NORDSummit! Don't miss the opportunity to present on topics like #OrphanDrug research, medical education advancement, patient community building, and #HealthEquity. Submit your research now: https://t.co/cEDta9pAGv https://t.co/a7bApC2cgk
-
-
Mashup Score: 1NORD Breakthrough Summit | Rare Disease Conference - 10 month(s) ago
NORD Summit is one of the largest events in rare disease, bringing together participants spanning the rare community.
Source: NORD Rare SummitCategories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 0FDA Approves Omaveloxolone to Treat Friedreich’s Ataxia - 11 month(s) ago
Omaveloxolone activates nuclear factor erythroid 2-related factor 2 (NrF2), a transcription factor that is impaired in patients with Friedreich’s ataxia.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0FDA Approves Aflibercept for Treating Retinopathy of Prematurity - 12 month(s) ago
This the fifth indication approved for aflibercept but the first approved orphan drug indication.d
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0FDA Approves Omaveloxolone to Treat Friedreich’s Ataxia - 1 year(s) ago
Omaveloxolone activates nuclear factor erythroid 2-related factor 2 (NrF2), a transcription factor that is impaired in patients with Friedreich’s ataxia.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0FDA Approves Aflibercept for Treating Retinopathy of Prematurity - 1 year(s) ago
This the fifth indication approved for aflibercept but the first approved orphan drug indication.d
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0FDA Approves Omaveloxolone to Treat Friedreich’s Ataxia - 1 year(s) ago
Omaveloxolone activates nuclear factor erythroid 2-related factor 2 (NrF2), a transcription factor that is impaired in patients with Friedreich’s ataxia.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1FDA Approves Omaveloxolone to Treat Friedreich’s Ataxia - 1 year(s) ago
Omaveloxolone activates nuclear factor erythroid 2-related factor 2 (NrF2), a transcription factor that is impaired in patients with Friedreich’s ataxia.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0FDA Approves Aflibercept for Treating Retinopathy of Prematurity - 1 year(s) ago
This the fifth indication approved for aflibercept but the first approved orphan drug indication.d
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Registration for the 2023 #NORDSummit is open! Join #RareDisease researchers and advocates in Washington, DC on October 16-17 to discuss breakthroughs in #OrphanDrug development, research, health policy, patient engagement, market accessibility, and more: https://t.co/vEDNBX0lOZ https://t.co/YSptURnUfX